Anixa Biosciences Inc (ANIX) income statement
ANIXNasdaqPharmaceutical PreparationsFiscal year ends October 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 9, 2026Score 6/30
$2.71+0.04 (+1.50%)
Close on Nov 18, 2026Market cap $94.21MP/E –Yield –
Anixa Biosciences Inc income statement
Ratios
Latest available, balances at Jul 31, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -62.2%
Financial strength
- Current ratio
- 8.54
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 80.1%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 6.51
- Dividend yield
- –
See a number that looks wrong?